Please ensure Javascript is enabled for purposes of website accessibility

How Risky Is Aurora Cannabis' Big Bet on Cannabis 2.0?

By Keith Speights - Oct 6, 2019 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The short answer: Riskier than ever before.

Every major Canadian cannabis producer is gearing up for what has been dubbed "Cannabis 2.0." The next stage in the process by which that country is legalizing adult-use recreational marijuana will bring several new types of cannabis-derived products to the market.

Aurora Cannabis (ACB 11.34%) is as excited about those new opportunities as any of its rivals. The company has invested heavily in anticipation of the market for them officially opening this month, although sales of those products won't begin until after a required 60-day notification window that ends in mid-December.

But Aurora is making a big bet on one type of product for the Cannabis 2.0 market. How risky is this bet?

Wooden dice, one in foreground and two in a blurred background

Image source: Getty Images.

Aurora's big bet

Some of Aurora's peers, notably including Canopy Growth and HEXO, have high expectations for cannabis-infused beverages. Aurora doesn't. Instead, it has mainly played up its soon-to-arrive opportunities in selling vape-related products.

In the company's fiscal 2019 third-quarter conference call in May, Aurora Chief Corporate Officer Cam Battley stated that he thinks that vapes will be "a terrific market segment that doesn't need a lot of market development." CEO Terry Booth chimed in that vapes, along with gummies, have been the best-selling cannabis derivative products in the U.S., and have achieved the highest profit margins.

Battley was asked in Aurora's Q4 conference call what percentage of investment the company has put into the different types of products it plans to launch in the Cannabis 2.0 market. He didn't provide details, but, in addition to edibles such as chocolates and mints, he noted that the company has "consistently indicated that we are looking at vapes."

Rising concerns

But its decision to heavily emphasize vape products was made well before health concerns related to vaping became a major issue in the U.S. As of late September, more than 800 cases of lung injury linked to vaping had been reported to the U.S. Centers for Disease Control and Prevention (CDC) in 46 states and the U.S. Virgin Islands.

The CDC is continuing to investigate these incidents. However, the agency's latest findings are that 77% of the reported cases involved products that contained THC, the primary psychoactive ingredient in cannabis.

Aurora's executives were asked during the Q4 conference call if they were concerned that the Canadian government could hold up the sale of vaping products as a result of the health issues connected to them. Battley wouldn't engage in speculation, but acknowledged that the company would "have to abide by what regulators say."

Battley noted that there had been no reported cases of illnesses linked to vaping in Canada. That was true at the time, but it isn't now. There has been one confirmed case of lung illness associated with vaping reported in Quebec, along with an unconfirmed incident in Ontario that remains under investigation.

A task force consisting of federal, provincial, and territorial health professionals in Canada has been formed to develop an approach for reporting any other cases of health issues linked to vaping. The province of Alberta is currently reviewing its tobacco and smoking laws with a special focus on addressing the potential negative impacts of vaping.

Risky business

Investing in marijuana stocks carries inherent risks, in large part because the industry is still at such an early stage of development. Anything that creates uncertainty only adds to these risks, and this vaping health scare is definitely creating uncertainty.

This issue could affect several Canadian cannabis producers that are hoping to boost their revenues by selling vaping products in the Cannabis 2.0 market. But no company has bet as heavily on vaping as Aurora has.

It's possible, of course, that the ongoing investigations could settle things down, and that the health concerns could evaporate. However, it's also possible that pressure could build for regulators to clamp down on vaping not only in the U.S. but in Canada as well. So far, that scenario seems unlikely. There's no question, though, that Aurora appears to be a riskier investment than ever.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurora Cannabis Stock Quote
Aurora Cannabis
ACB
$1.67 (11.34%) $0.17
Canopy Growth Stock Quote
Canopy Growth
CGC
$3.09 (14.44%) $0.39
HEXO Stock Quote
HEXO
HEXO
$0.23 (11.43%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.